Management of substance abuse

The health and social effects of nonmedical cannabis use

New WHO publication on cannabis


References

Chapter 1

Global Burden of Disease Study 2013 Collaborators (2015). Global Burden of Diseases, Injuries, and Risk Factors Study 2013. Lancet. 386;9995:743–800.

Madras BK (2015). Update of cannabis and its medical use. Report to the WHO Expert Committee on Drug Dependence (http://www.who.int/medicines/access/controlled-substances/6_2_cannabis_update.pdf?ua=1, accessed 16 February 2016).

UNODC (2015). World drug report 2015. Vienna: United Nations Office on Drugs and Crime.

WHO (1997). Cannabis: a health perspective and research agenda. Geneva: World Health Organization:46.

WHO (2015). WHO Expert Committee on Drug Dependence: thirty-seventh report. Geneva: World Health Organization (in press).


Chapter 2

Ahmed SA, Ross SA, Slade D, Radwan MM, Zulfiqar F, Matsumoto RR, et al. (2008). Cannabinoid ester constituents from high-potency Cannabis sativa. J Nat Prod. 71(4):536–42.

APA (2013). Diagnostic and statistical manual of mental Disorders, fifth edition. Arlington (VA): American Psychiatric Association.

Azorlosa JL, Greenwald MK, Stitzer ML (1995). Marijuana smoking: effects of varying puff volume and breathhold duration. J Pharmacol Exp Ther. 272(2):560–9.

Azorlosa JL, Heishman SJ, Stitzer ML, Mahaffey JM (1992). Marijuana smoking: Effect of varying delta-9-tetrahydrocannabinol content and number of puffs. J Pharmacol Exp Ther. 261(1):114–22.

Bloor RN, Wang TS, Spanel P, Smith D (2008). Ammonia release from heated 'street' cannabis leaf and its potential toxic effects on cannabis users. Addiction. 103(10):1671–7.

Brands B, Sproule B, Marshman J, editors (1998). Drugs & drug abuse, third edition. Toronto: Addiction Research Foundation.

Bruci Z, Papoutsis I, Athanaselis S, Nikolaou P, Pazari E, Spiliopoulou C, et al. (2012). First systematic evaluation of the potency of Cannabis sativa plants grown in Albania. Forensic Sci Int. 222(1-3):40–6.

Cannon DS, Clark LA, Leeka JK, Keefe CK (1993). A reanalysis of the Tridimensional Personality Questionnaire (TPQ) and its relation to Cloninger's Type 2 Alcoholism. Psychol Assessment. 5:62–6.

Moffat AC, Osselton MD, Widdop B, editors (2004). Clarke’s analysis of drugs and poisons, third edition. Volume 2:743.London: Pharmaceutical Press.

Coffey C, Carlin JB, Lynskey M, Li N, Patton GC (2003). Adolescent precursors of cannabis dependence: Findings from the Victorian Adolescent Health Cohort Study. Brit J Psychiat. 182:330–6.

Collins D, Abadi MH, Johnson K, Shamblen S, Thompson K (2011). Non-medical use of prescription drugs among youth in an Appalachian population: prevalence, predictors, and implications for prevention. J Drug Educ. 41(3):309–26

Costello EJ, Angold A (2011). Causal thinking in developmental disorders. In: Shrout PE,

Keyes KM, Ornstein K, editors. Causality and Psychopathology: finding the determinants of disorders and their cures. Oxford: University Press:27996.

Daniel JZ, Hickman M, Macleod J, Wiles N, Lingford-Hughes A, Farrell M, et al. (2009). Is socioeconomic status in early life associated with drug use? A systematic review of the evidence. Drug Alcohol Rev. 28(2):14253.

Davy Smith G (2011). Obtaining robust causal evidence from observational studies: Can genetic epidemiology help? In: Shrout PE, Keyes KM, Ornstein K, editors. Causality and psychopathology: finding the determinants of disorders and their cures. Oxford: University Press:20651.

Degenhardt L, Dierker L, Chiu WT, Medina-Mora, ME, Neumark Y, Sampson N, et al. (2010). Evaluating the drug use "gateway" theory using cross-national data: consistency and associations of the order of initiation of drug use among participants in the WHO World Mental Health Surveys. Drug and Alcohol Depen. 108(1-2):8497.

Eisenberg E, Ogintz M, Almog S (2014). The pharmacokinetics, efficacy, safety, and ease of use of a novel portable metered-dose cannabis inhaler in patients with chronic neuropathic pain: a phase 1a study. J Pain Palliat Care Pharmacother. 28(3): 21625.

ElSohly MA, Ross SA, Mehmedic Z, Arafat R, Yi B, Banahan BF (2000). Potency trends of delta(9)-THC and other cannabinoids in confiscated marijuana from 1980-1997. J Forensic Sci. 45(1):2430.

Elsohly MA, Slade D (2005). Chemical constituents of marijuana: the complex mixture of natural cannabinoids. Life Sci. 78(5):53948.

EMCDDA (2004). EMCDDA insights: an overview of cannabis potency in Europe. Luxembourg: Office for Official Publications of the European Communities.

EMCDDA (2015a). European drug report 2015: trends and developments. Lisbon: European Monitoring Centre for Drugs and Drug Addiction (http://www.emcdda.europa.eu/edr2015, accessed 8 August 2015).

EMCDDA (2015b). EMCDDA perspectives on drugs, new developments in Europe’s cannabis market. Lisbon: European Monitoring Centre for Drugs and Drug Addiction.

Fehr K, Kalant H, editors (1983). Cannabis and health hazards: proceedings of an ARF/WHO scientific meeting on adverse health and behavioral consequences of cannabis use. Toronto: Addiction Research Foundation.Fergusson DM, Horwood LJ, Lynskey MT (1994). Parental separation, adolescent psychopathology, and problem behaviors. J Am Acad Child Psy. 33(8):112231.

Fergusson DM, Horwood LJ, Beautrais AL (2003). Cannabis and educational achievement. Addiction. 98(12):168192.

Fergusson D, Horwood L, Swain-Campbell N (2003). Cannabis dependence and psychotic symptoms in young people. Psychol Med. 33:1521.

Fergusson D, Boden J, Horwood L (2008). The developmental antecedents of illicit drug use: evidence from a 25-year longitudinal study. Drug Alcohol Depend. 96(1-2):16577.

Fergusson DM, Boden J, Horwood L (2015). Psychosocial sequelae of cannabis use and implications for policy: findings from the Christchurch Health and Development Study. Soc Psychiatry Psychiatr Epidemiol. 50:131726.

Gaoni Y, Mechoulam R (1964). Isolation, structure and partial synthesis of an active constituent of hashish. J Am Chem Soc. 86:16467.

Gerra G, Angioni L, Zaimovic A, Moi G, Bussandri M, Bertacca S, et al. (2004). Substance use among high school students: relationships with temperament, personality traits, and parental care perceptions. Subst Use Misuse. 39(2):34567.

Gloss D (2015). An overview of products and bias in research. Neurotherapeutics. 12(4):7314.

Hall WD, Degenhardt L (2007). Prevalence and correlates of cannabis use in developed and developing countries. Curr Opin Psychiatry. 20(4):3937.

Hall W, Degenhardt L, Teesson M (2009). Understanding comorbidity between substance use, anxiety and affective disorders: broadening the research base. Addict Behav. 34:52630.

Hall WD, Pacula RL (2010). Cannabis use and dependence: public health and public policy (reissue of first edition 2003). Cambridge: Cambridge University Press.

Hall WD (2015). What has epidemiological research revealed about the adverse health effects of cannabis in the past 20 years? Addiction. 110:1935.

Hawkins J, Catalano R, Miller J (1992). Risk and protective factors for alcohol and other drug problems in adolescence and early adulthood: implications for substance abuse prevention. Psychol Bull . 112:64105.

Hoch E, Bonnet U, Thomasius R, Ganszer F, Havemann-Reinecke U, Preuus UW (2015). Risks associated with non-medical use of cannabis. Dtsch Arztebl Int [German Medical Journal International]. 112:2718.

Hill A (1965). The Environment and Disease: Association or Causation? Proc R Soc Med. May; 58(5): 295–300.PMCID: PMC1898525

Iversen L (2007). The science of marijuana, second edition. Oxford: Oxford University Press.

Izzo AA, Borrelli F, Capasso R, Di Marzo V, Mechoulam R (2009). Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends Pharmacol Sci. 30(10):51527.

Kandel DB, Andrews K (1987). Processes of adolescent socialisation by parents and peers. Int J Addict. 22:319–42.

Kandel D (1993). Social demography of drug use. In: Bayer R, Oppenheimer GM, editors. Drug policy, illicit drugs in a free society. Cambridge: Cambridge University Press:2477.

Kendler K, Chen X, Dick D, Maes H, Gillespie N, Neale MC, et al. (2012). Recent advances in the genetic epidemiology and molecular genetics of substance use disorders. Nat Neurosci. 15:181–9.

King KM, Chassin L (2004). Mediating and moderated effects of adolescent behavioral under control and parenting in the prediction of drug use disorders in emerging adulthood. Psychol Addict Behav. 18:239–49.

Korhonen T, Huizink AC, Dick DM, Pulkkinen L, Rose RJ, Kapiro J (2008). Role of individual, peer and family factors in the use of cannabis and other illicit drugs: a longitudinal analysis among Finnish adolescent twins. Drug Alcohol Depend. 97(1-2):33–43.

Lascala E, Friesthler B, Gruenwald PJ (2005). Population ecologies of drug use, drinking and related problems. In: Stockwell T, Gruenwald PJ, Toumbourou JW, et al., editors. Preventing harmful substance use: the evidence base for policy and practice. Chichester: John Wiley & Sons.

Lipkus IM, Barefoot JC, Williams RB, Siegler IC (1994). Personality measures as predictors of smoking initiation and cessation in the UNC Alumni Heart Study. Health Psychol. 13(2):149–55.

Lopez-Quintero C, Pérez de los Cobos J, Hasin DS, Okuda M, Wang S, Grant BF, et al. (2011). Probability and predictors of transition from first use to dependence on nicotine, alcohol, cannabis, and cocaine: results of the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). Drug Alcohol Depend. 115(1-2):120–30.

Lynskey M, Hall W (2000). The effects of adolescent cannabis use on educational attainment: a review. Addiction. 95(11):1621–30.

Lynskey MT, Fergusson DM, Horwood LJ (1994). The effect of parental alcohol problems on rates of adolescent psychiatric disorders. Addiction. 89(10):1277–86.

Lynskey MT, Fergusson DM (1995). Childhood conduct problems and attention deficit behaviors and adolescent alcohol, tobacco and illicit drug use. J Abnorm Child Psych. 23:281–302.Martin B, Cone E (1999). Chemistry and pharmacology of cannabis. In: Kalant H, Corrigal W, Hall W, et al., editors. The health effects of cannabis. Toronto: Centre for Addiction and Mental Health:19–68.

Mechoulam R, Hanus L (2012). Other cannabinoids. In: Castle D, Murray RM, D’Souza DC, editors. Marijuana and madness, second edition. Cambridge: Cambridge University Press:17–22.

Mednick SC, Christakis NA, Fowler JH (2010). The spread of sleep loss influences drug use in adolescent social networks. PLoS One. 5(3):e9775.

Mehmedic Z, Chandra S, Slade D, Denham H, Foster S, Patel AS, et al. (2010). Potency trends of Delta9-THC and other cannabinoids in confiscated cannabis preparations from 1993 to 2008. J Forensic Sci. 55(5):1209–17.

Niesink RJ, Rigter S, Koeter MW, Brunt TM (2015). Potency trends of Δ(9)-tetrahydrocannabinol, cannabidiol and cannabinol in cannabis in the Netherlands: 2005-15. Addiction. 110(12):1941–50.

ONDCP (2007). Study finds highest levels of THC in U.S. marijuana to date. News release. Washington (DC): Office of National Drug Control Policy.

Pinchevsky GM, Arria AM, Caldeira KM, Garnier-Dykstra LM, Vincent KB, O’Grady KE (2012). Marijuana exposure opportunity and initiation during college: parent and peer influences. Prev Sci. 13:43–54.

Radwan MM, Elsohly MA, Slade D, Ahmed SA, Wilson L, El-Alfy AT, et al. (2008). Non-cannabinoid constituents from a high potency Cannabis sativa variety. Phytochemistry. 69(14): 2627–33.

Radwan MM, ElSohly MA, El-Alfy AT, Ahmed SA, Slade D, Husni AS, et al. (2015). Isolation and pharmacological evaluation of minor cannabinoids from high-potency Cannabis sativa. J Nat Prod. 78(6):1271–6.

Richmond RC, Al-Amin A, Smith GD, Relton CL (2014). Approaches for drawing causal inferences from epidemiological birth cohorts: a review. Early Hum Dev. 90(11):769–80.

Schulenberg JE, Merline AC, Johnston LD, O’Malley PM, Bachman JG, Laetz VB (2005). Trajectories of marijuana use during the transition to adulthood: the big picture based on national panel data. J of Drug Issues. 35:255–80.

Stone AL, Becker LG, Huber AM, Catalano RF (2012). Review of risk and protective factors of substance use and problem use in emerging adulthood. Addict Behav. 37:747–75.

Swift W, Wong A, Li KM, Arnold JC, McGregor IS (2013). Analysis of cannabis seizures in NSW, Australia: cannabis potency and cannabinoid profile. PLoS One. 8(7):e70052.

Townsend L, Flisher AJ, King G (2007). A systematic review of the relationship between high school dropout and substance use. Clin Child Fam Psychol Rev. 10(4):295–317.

Tu AW, Ratner PA, Johnson JL (2008). Gender differences in the correlates of adolescents’ cannabis use. Subst Use Misuse. 43(10):1438–63.

UNODC (2015). World drug report 2015. Vienna: United Nations Office on Drugs and Crime.

von Sydow K, Lieb R, Pfister H, Höfler M, Wittchen HU (2002). What predicts incident use of cannabis and progression to abuse and dependence? A 4-year prospective examination of risk factors in a community sample of adolescents and young adults. Drug Alcohol Depend. 68(1):49–64.

Wilsey B, Marcotte T, Deutsch R, Gouaux B, Sakai S, Donaghe H (2013). Low-dose vaporized cannabis significantly improves neuropathic pain. J Pain. 14(2):136–48.

WHO (1992). The ICD-10 classification of mental and behavioural disorders. Clinical descriptions and diagnostic guidelines . Geneva: World Health Organization.

WHO (1993). The ICD-10 classification of mental and behavioural disorders. Diagnostic criteria for research. Geneva: World Health Organization.

Wymbs BT, McCarty CA, King KM, McCauley E, Vander Stoep A, Baer JS, et al. (2012). Callous-unemotional traits as unique prospective risk factors for substance use in early adolescent boys and girls. J Abnorm Child Psych. 40(7):1099–110.

Zamengo L, Frison G, Bettin C, Sciarrone R (2014). Variability of cannabis potency in the Venice area (Italy): a survey over the period 2010-2012. Drug Test Anal. 6(1-2):46–51.


Chapter 3

Anthony J, Warner L, Kessler R (1994). Comparative epidemiology of dependence on tobacco, alcohol, controlled substances and inhalants: basic findings from the National Comorbidity Survey. Exp and Clin Psychopharm. 2(3):244–68.

Anthony JC (2006). The epidemiology of cannabis dependence. In: Roffman RA, Stephens RS, editors. Cannabis dependence: its nature, consequences and treatment. Cambridge: Cambridge University Press:58–105.

Bhana A (2015). Adolescent cannabis use in Africa [background paper submitted to the WHO Scientific Meeting on Harms to Health Due to Cannabis, Stockholm, 2123 April 2015].

Calabria B, Degenhardt L, Briegleb C, Vos T, Hall W, Lysneky M, et al. (2010). Systematic reviews of prospective studies investigating “remission” from amphetamine, cannabis, cocaine and opioid dependence. Addict Behav. 35:741–9.

Castillo Carniglia A (2015). Large increase in adolescent marijuana use in Chile. Addiction. 110(1):185–6.

Chopra RN, Chopra GS, Chopra IC (1942). Cannabis sativa in relation to mental diseases and crime in India. Indian J Med Res. 30:155–71.

Comisión Interamericanana para el Control del Abuso de Drogas (CICAD) (Inter-American Drug Abuse Control Commission) (2015). Informe sobre uso de drogas en las Américas 2015. Washington (DC): CICAD (www.cicad.oas.org/apps/Document.aspx?Id=3209, accessed 05 September 2015).

Compton WM, Grant BF, Colliver JD, Glantz MD, Stinson FS (2004). Prevalence of marijuana use disorders in the United States: 1991-1992 and 2001-2002. JAMA. 291(17):2114–21.

Cooper ZD, Haney M (2014). Investigation of sex-dependent effects of cannabis in daily cannabis smokers. Drug Alcohol Depend. 136:85–91.

Davis JM, Mendelson B, Berkes JJ, Suleta K, Corsi KF, Booth RE (2015). Public health effects of medical marijuana legalization in Colorado. Am J Prev Med. doi:10.1016/j.amepre.2015.06.034 (Epub ahead of print).

Degenhardt L, Hall WD (2012). Extent of illicit drug use and dependence, and their contribution to the global burden of disease. Lancet. 379(9810):55–70.

Degenhardt L, Ferrari AJ, Calabria B, Hall WD, Norman R, McGrath J, et al. (2013). The global epidemiology and contribution of cannabis use and dependence to the global burden of disease: results from the GBD 2010 Study. PLoS One. 8(10):e76635.

Dines AM, Wood DM, Galicia M, Yates CM, Heyerdahl F, Hovda KE, et al. (2015a). Presentations to the emergency department following cannabis use – a multi-centre case series from ten European countries. J Med Toxicol. 11(4):415-21.

Dines AM, Wood DM, Yates C, Heyerdahl F, Hovda KE, Giraudon I, et al. (2015b). Acute recreational drug and new psychoactive substance toxicity in Europe: 12 months data collection from the European Drug Emergencies Network (Euro-DEN). Clin Toxicol. 53(9):893-900.

El Omari F, Toufiq J (2015). The Mediterranean School Survey Project on Alcohol and Other Drugs in Morocco. Addicta. 2:30–9.

EMCDDA (2014). European Drug Report 2014: trends and developments [online publication]. Luxembourg: Publications Office of the European Union (www.emcdda.europa.eu/attachements.cfm/att_228272_EN_TDAT14001ENN.pdf, accessed 05 September 2015).

EMCDDA (2015a). European Drug Report 2015: trends and developments [online publication]. Luxembourg: Publications Office of the European Union (http://www.emcdda.europa.eu/edr2015, accessed 05 September 2015).

EMCDDA (2015b). EMCDDA Perspectives on Drugs: new developments in Europe’s cannabis market. Lisbon, European Monitoring Centre for Drugs and Drug Addiction.

EMCDDA (2015c). Statistical bulletin [online publication]. Lisbon: European Monitoring Centre for Drugs and Drug Addiction (http://www.emcdda.europa.eu/data/stats2015, accessed 05 September 2015).

Hall WD, Pacula RL (2010). Cannabis use and dependence: public health and public policy, (reissue of first edition 2003). Cambridge: Cambridge University Press.

Hall WD (2015). What has epidemiological research revealed about the adverse health effects of cannabis in the past 20 years? Addiction. 110:19–35.

Hasin DS, Saha TD, Kerridge BT, Goldstein RB, Chou SP, Zhang H, et al. (2015). Prevalence of marijuana use disorders in the United States between 2001-2002 and 2012-2013. JAMA Psychiatry. 72(12):1235–42.

Horta RL, Horta BL, da Costa AW, do Prado RR, Oliveira-Campos M, Malta DC (2014). Lifetime use of illicit drugs and associated factors among Brazilian schoolchildren, National Adolescent School-based Health Survey (PeNSE 2012). Rev Bras Epidemiol [Brazilian Journal of Epidemiology]. 17:31–45.

Jungerman FS, Menezes PR, Pinsky I, Zaleski M, Caetano R, Laranjeira R (2009). Prevalence of cannabis use in Brazil: data from the I Brazilian National Alcohol Survey (BNAS). Addict Behav. 35(3):190-3. doi:10.1016/j.addbeh.2009.09.022.

Kaar SJ, Gao CX, Lloyd B, Smith K, Lubman DI (2015). Trends in cannabis-related ambulance presentations from 2000 to 2013 in Melbourne, Australia. Drug Alcohol Depend. 155:24–30.

Kadri N, Agoub M, Assouab F, Tazi MA, Didouh A, Stewart R, et al. (2010). Moroccan national study on prevalence of mental disorders: a community-based epidemiological study. Acta Psychiatrica Scandinavica. 122:340.

Liakoni E, Dolder PC, Rentsch K, Liechti ME (2015). Acute health problems due to recreational drug use in patients presenting to an urban emergency department in Switzerland. Swiss Med Wkly. 145:w14166.

NACADA (2007). Rapid assessment of drug and substance abuse in Kenya. Nairobi: National Authority for the Campaign Against Drug Abuse (http://www.nacada.go.ke/wp-content/uploads/2010/06/rapidassessment-web.pdf, accessed 6 September 2015).

NACADA (2012). Rapid assessment of drug and substance abuse in Kenya. Nairobi: National Authority for the Campaign Against Drug Abuse.

NIH (2012). National Epidemiologic Survey on Alcohol and Related Conditions-III (NESARC-III). Bethesda: National Institutes of Health.

SAMHSA (2012). Drug Abuse Warning Network (DAWN) 2010: national estimates of drug related emergency department visits. HHS publication no. (SMA)12-4733, DAWN series D-38. Rockville (MD): Substance Abuse and Mental Health Services Administration.

SAMHSA (2013). Drug Abuse Warning Network (DAWN) 2011: national estimates of drug related emergency department visits. HHS publication no. (SMA) 13-4760, DAWN Series D-39. Rockville (MD): Substance Abuse and Mental Health Services Administration.

SENDA (2013). Décimo estudio nacional de drogas en población general de Chile 2012 [tenth national study of drugs in the general population of Chile]. Santiago: Servicio Nacional para la Prevención y Rehabilitación del Consumo de Droga y Alcohol; Observatorio Chileno de Drogas. (http://www.senda.gob.cl/wpcontent/uploads/2011/04/2012_Decimo_EstudioNacional.pdf, accessed 18 August 2015).

SENDA (2014). Décimo estudio nacional de drogas en población escolar de Chile 2013 [tenth national study of drugs in the school population of Chile]. Santiago: Servicio Nacional para la Prevención y Rehabilitación del Consumo de Droga y Alcohol ; Observatorio Chileno de Drogas.

SENDA (2015). Décimo primer estudio nacional de drogas en población general de Chile [eleventh national study of drugs in the general population of Chile]. Santiago: : Servicio Nacional para la Prevención y Rehabilitación del Consumo de Droga y Alcohol; Observatorio Chileno de Drogas (http://www.senda.gob.cl/media/2015/08/Informe-Ejecutivo-ENPG-2014.pdf, accessed 18 August 2015).

Roxburgh A, Hall WD, Degenhardt L, Mclaren J, Black E, Copeland J, et al. (2010). The epidemiology of cannabis use and cannabis-related harm in Australia 1993-2007. Addiction. 105(6):1071–9.

Smith DE (1968). Acute and chronic toxicity of marijuana. J Psychedelic Drugs. 2:37–47.

Thomas H (1993). Psychiatric symptoms in cannabis users. Brit J Psychiat. 163:141–9.

UNIAD/INPAD (2012). Unidade de pesquisas em álcool e drogas/Instituto nacional de ciència e tecnologia para políticas públicas do álcool e outras drogas. LENAD II (Levantamento Nacional de Álcool e Drogas II [Second national survey of alcohol and drugs]). São Paulo: Universidade federal de São Paulo (http://inpad.org.br/wp-content/uploads/2014/03/Lenad-II-Relat%C3%B3rio.pdf, accessed 05 September 2015).

UNODC (2015). World drug report 2015. Vienna: United Nations Office on Drugs and Crime.

Weil A (1970). Adverse reactions to marijuana, classification, and suggested treatment. NEJM. 282:997–1000.

WHO (2010). ATLAS on substance use (2010): resources for the preventions and treatment of substance use disorders. Geneva: World Health Organization.


Chapter 4

Anthony JC (2006). The epidemiology of cannabis dependence. In: Roffman RA, Stephens RS, editors. Cannabis dependence: its nature, consequences and treatment. Cambridge: Cambridge University Press:58–105.

Ashtari M, Avants B, Cyckowski L, Cervellione KL, Roofeh D, Cook P, et al. (2011). Medial temporal structures and memory functions in adolescents with heavy cannabis use. J Psychiat Res. 45(8):1055–66.

Batalla A, Bhattacharyya S, Yücel M, Fusar-Poli P, Crippa JA, Nogué S, et al. (2013). Structural and functional imaging studies in chronic cannabis users: a systematic review of adolescent and adult findings. PLoS One. 8(2):e55821. doi:10.1371/journal.pone.0055821.

Bidwell LC, Metrik J, McGeary J, Palmer RH, Francazio S, Knopik VS (2013). Impulsivity, variation in the cannabinoid receptor (CNR1) and fatty acid amide hydrolase (FAAH) genes, and marijuana-related problems. J Stud Alcohol Drugs. 74(6):867–78.

Bloomfield MA, Morgan CJ, Egerton A, Kapur S, Curran HV, Howes OD (2014). Dopaminergic function in cannabis users and its relationship to cannabis-induced psychotic symptoms. Biol Psychiatry. 75(6):470–8.

Bossong MG, Jager G, Bhattacharyya S, Allen P (2014). Acute and non-acute effects of cannabis on human memory function: a critical review of neuroimaging studies. Curr Pharm Des. 20(13):2114–25.

Cascio MG, Pertwee RG (2012). The function of the endocannabinoid system. In: Castle D, Murray R, D’Souza DC, editors. Marijuana and madness. Cambridge: Cambridge University Press:23–34.

Cheetham A, Allen NB, Whittle S, Simmons JG, Yücel M, Lubman DI (2012). Orbitofrontal volumes in early adolescence predict initiation of cannabis use: a 4-year longitudinal and prospective study. Biol Psychiatry. 71(8):684–92.

Churchwell JC, Lopez-Larson M, Yurgelun-Todd DA (2010). Altered frontal cortical volume and decision making in adolescent cannabis users. Front Psychol. 14(1):225.

Cousijn J, Wiers RW, Ridderinkhof KR, van den Brink W, Veltman DJ, Goudriaan AE (2012). Grey matter alterations associated with cannabis use: results of a VBM study in heavy cannabis users and healthy controls. Neuroimage. 59(4):3845–51.

Crean RD, Crane NA, Mason BJ (2011). An evidence based review of acute and long-term effects of cannabis use on executive cognitive functions. J Addict Med. 5(1):1–8.

Creemers HE, Buil JM, van Lier PA, Keijsers L, Meeus W, Koot HM, et al. (2015). Early onset of cannabis use: does personality modify the relation with changes in perceived parental involvement? Drug Alcohol Depend. 146:61–7. doi: 10.1016/j.drugalcdep.2014.11.004.

Danielsson AK, Falkstedt D, Hemmingsson T, Allebeck P, Agardh E (2015). Cannabis use among Swedish men in adolescence and the risk of adverse life course outcomes: results from a 20 year-follow-up study. Addiction. 10(11):1794–802. doi:10.1111/add.13042.

Day NL, Leech SL, Goldschmidt L (2011). The effects of prenatal marijuana exposure on delinquent behaviors are mediated by measures of neurocognitive functioning. Neurotoxicol Teratol. 33(1):129–36.

Di Forti M, Sallis H, Allegri F, Trotta A, Ferraro L, Stilo SA, et al. (2014). Daily use, especially of high-potency cannabis, drives the earlier onset of psychosis in cannabis users. Schizophr Bull. 40(6):1509–17.

DiNieri JA, Hurd YL (2012). Rat models of prenatal and adolescent cannabis exposure. Methods Mol Biol. 829:231–42.

DiNieri JA, Wang X, Szutorisz H, Spano SM, Kaur J, Casaccia P, et al. (2011). Maternal cannabis use alters ventral striatal dopamine D2 gene regulation in the offspring. Biol Psychiatry. 70(8):763–9.

EMCDDA (2015a). European Drug Report 2015: trends and developments. Lisbon: European Monitoring Centre for Drugs and Drug Addiction (http://www.emcdda.europa.eu/edr2015, accessed 05 September 2015).

EMCDDA (2015b). EMCDDA perspectives on drugs, new developments in Europe’s cannabis market. Lisbon: European Monitoring Centre for Drugs and Drug Addiction.

Fried P, Watkinson B, Gray R (2005). Neurocognitive consequences of marihuana – a comparison with pre-drug performance. Neurotoxicol Teratol. 27(2):231–9.

Gerra G, Zaimovic A, Castaldini L, Garofano L, Manfredini M, Somaini L, et al. (2010). Relevance of perceived childhood neglect, 5-HTT gene variants and hypothalamus-pituitary-adrenal axis dysregulation to substance abuse susceptibility. Am J Med Genet B Neuropsychiatr Genet. 153B(3):715–22.

Goldschmidt L, Day NL, Richardson GA (2000). Effects of prenatal marijuana exposure on child behavior problems at age 10. Neurotoxicol Teratol. 22(3):325–36.

Goldschmidt L, Richardson GA, Cornelius MD, Day NL (2004). Prenatal marijuana and alcohol exposure and academic achievement at age 10. Neurotoxicol Teratol. 26(4):521–32.

Goldschmidt L, Richardson GA, Willford J, Day NL (2008). Prenatal marijuana exposure and intelligence test performance at age 6. J Am Acad Child Psy. 47(3):254–63.

Gruber SA, Sagar KA, Dahlgren MK, Racine M, Lukas SE (2012). Age of onset of marijuana use and executive function. Psychol Addict Behav. 26(3):496.

Hall WD (2015). What has epidemiological research revealed about the adverse health effects of cannabis in the past 20 years? Addiction. 110:1935.

Hartman RL, Huestis MA (2013). Cannabis effects on driving skills. Clin Chem. 59(3):478–92. doi:10.1373/clinchem.2012.194381.

Hayatbakhsh MR, Najman JM, Bor W, O’Callaghan MJ, Williams GM (2009). Multiple risk factor model predicting cannabis use and use disorders: a longitudinal study. Am J Drug Alcohol Abuse. 35(6):399–407.

Hu SS, Mackie K (2015). Distribution of the endocannabinoid system in the central nervous system. In: Pertwee RG, editor. Handbook of Experimental Pharmacology. New York (NY): Springer:231:59–93.

Huestis MA, Gorelick DA, Heishman SJ, Preston KL, Nelson RA, Moolchan ET, et al. (2001). Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716. Arch Gen Psychiatry. 58(4):3228.

Iversen L (2012). How cannabis works in the human brain. In: Castle D, Murray R, D’Souza DC, editors. Marijuana and madness. Cambridge, Cambridge University Press:1–11.

Jacobus J, Tapert SF (2014). Effects of cannabis on the adolescent brain. Curr Pharm Des. 20(13):2186–93.

Konijnenberg C (2015). Methodological Issues in Assessing the Impact of Prenatal Drug Exposure. Substance;9(Suppl 2):39-44. PMID: 26604776

Lopez-Larson MP, Bogorodzki P, Rogowska J, McGlade E, King JB, Terry J, et al. (2011). Altered prefrontal and insular cortical thickness in adolescent marijuana users. Behav Brain Res. 220(1):164–172.

Lopez-Larson MP, Rogowska J, Yurgelun-Todd D (2015). Aberrant orbitofrontal connectivity in marijuana smoking adolescents. Dev Cogn Neurosci. 16:54–62.

Lorenzetti V, Solowij N, Whittle S, Fornito A, Lubman DI, Pantelis C et al. (2015). Gross morphological brain changes with chronic, heavy cannabis use. Br J Psychiatry. 206(1):77-8.

Lorenzetti V, Solowij N, Fornito A, Lubman DI, Yücel M (2014). The association between regular cannabis exposure and alterations of human brain morphology: an updated review of the literature. Curr Pharm Des. 20(13):2138–67.

Lorenzetti V, Lubman DI, Fornito A, Whittle S, Takagi MJ, Solowij N, et al. (2013). The impact of regular cannabis use on the human brain: a review of structural neuroimaging studies. In: Miller PM, editor. Biological research on addiction. San Diego (CA): Academic Press: 711–28.

Mackie K (2005). Distribution of cannabinoid receptors in the central and peripheral nervous system. Handb Exp Pharmacol. (168):299–325.

Madras BK (2015). Update of cannabis and its medical use. Report to the WHO Expert Committee on Drug Dependence (http://www.who.int/medicines/access/controlled-substances/6_2_cannabis_update.pdf?ua=1 , accessed 16 February 2016).

Matochik JA, Eldreth DA, Cadet JL, Bolla KI (2005). Altered brain tissue composition in heavy marijuana users. Drug Alcohol Depend. 77(1):23–30.

Meier MH, Caspi A, Ambler A, Harrington H, Houts R, Keefe RS, et al. (2012). Persistent cannabis users show neuropsychological decline from childhood to midlife. Proc Natl Acad Sci U S A, 109(40):E2657–64.

Mena I, Dörr A, Viani S, Neubauer S, Gorostegui ME, Dörr MP (2013). Efectos del consumo de marihuana en escolares sobre funciones cerebrales demostrados mediante pruebas neuropsicológicas e imágenes de neuro-SPECT [Effects of consuming marijuana on school students’ brain functions demonstrated through neuropsychological testing and neuro-SPECT imaging]. Salud mental. 36:367–74.

Moffitt TE, Meier MH, Caspi A, Poulton R (2013). Reply to Rogeberg and Daly: no evidence that socioeconomic status or personality differences confound the association between cannabis use and IQ decline. Proc Natl Acad Sci U S A. 110(11):E980–2.

Muro I, Rodríguez A (2015). Age, sex and personality in early cannabis use. Eur Psychiatry. 30(4):469–73.

Noland JS, Singer LT, Short EJ, Minnes S, Arendt RE, Kirchner HL, et al. (2005). Prenatal drug exposure and selective attention in preschoolers. Neurotoxicol Teratol. 27(3):429–38.

Pistis M, Perra S, Pillolla G, Melis M, Muntoni AL, Gessa GL (2004). Adolescent exposure to cannabinoids induces long-lasting changes in the response to drugs of abuse of rat midbrain dopamine neurons. Biol Psychiatry. 56(2):86–94.

Pope HG, Gruber AJ, Hudson JI, Cohane G, Huestis MA, Yurgelun-Todd D (2003). Early-onset cannabis use and cognitive deficits: what is the nature of the association? Drug Alcohol Depend. 69(3):303–10.

Schneider M (2012). The impact of pubertal exposure to cannabis on the brain: a focus on animal studies. In: Castle D, Murray R, D’Souza DC, editors. Marijuana and madness Cambridge: Cambridge University Press:82–90.

Solowij N, Jones KA, Rozman ME, Davis SM, Ciarrochi J, Heaven PC, et al. (2011). Verbal learning and memory in adolescent cannabis users, alcohol users and non-users. Psychopharmacology. 216(1):131–44.

Solowij N, Pesa N (2012). Cannabis and cognition: short and long-term effects. In: Castle D, Murray R, D’Souza DC, editors. Marijuana and madness, second edition. Cambridge: Cambridge University Press:91-102.

Sonon KE, Richardson GA, Cornelius JR, Kim KH, Day NL (2015). Prenatal marijuana exposure predicts marijuana use in young adulthood. Neurotoxicol Teratol. 47:10–5.

Tortoriello G, Morris CV, Alpar A, Fuzik J, Shirran SL, Calvigioni D, et al. (2014). Miswiring the brain: Delta9-tetrahydrocannabinol disrupts cortical development by inducing an SCG10/stathmin-2 degradation pathway. EMBO Journal. 33(7):668–85.

van der Pol P, Liebregts N, de Graaf R, Korf DJ, van den Brink W, van Laar M (2013). Predicting the transition from frequent cannabis use to cannabis dependence: a three-year prospective study. Drug Alcohol Depend. 133(2):352-9. doi:10.1016/j.drugalcdep.2013.06.009.

Verweij KJ, Zietsch BP, Lysnkey MT, Medland SE, Neale MC, Martin NG, et al. (2010). Genetic and environmental influences on cannabis use initiation and problematic use: a meta-analysis of twin studies. Addiction. 105(3):417–30.

Volkow ND, Baler RD, Compton WM, Weiss SR (2014a). Adverse health effects of marijuana use. NEJM. 370(23):2219–27.

Volkow ND, Wang GW, Telang F, Fowler JS, Alexoff D, Logan J, et al. (2014b). Decreased dopamine brain reactivity in marijuana abusers is associated with negative emotionality and addiction severity. Proc Natl Acad Sci U S A. 111(30):E3149–E3156.

Volkow N (2015). Cannabis and the central nervous system [background paper submitted to the WHO Scientific Meeting on Harms to Health due to Cannabis, Stockholm, 21-32 April 2015].

Yücel M, Solowij N, Respondek C, Whittle S, Fornito A, Pantelis C, et al. (2008). Regional brain abnormalities associated with long-term heavy cannabis use. Arch Gen Psychiatry. 65:694–701.

Yücel M, Lorenzetti V, Suo C, Zalesky A, Fornito A, Takagi MJ, et al. (2016). Hippocampal harms, protection and recovery following regular cannabis use. Transl Psychiatry. 6:e710.

Zalesky A, Solowij N, Yücel M, Lubman DI, Takagi M, Harding IH, et al. (2012). Effect of long-term cannabis use on axonal fibre connectivity. Brain. 135(Pt 7):2245–55.


Chapter 5

Asbridge M, Hayden JA, Cartwright JL (2012). Acute cannabis consumption and motor vehicle collision risk: systematic review of observational studies and meta-analysis. BMJ. 344:14–7.

Asbridge M, Mann R, Cusimano MD, Trayling C, Roerecke M, Tallon JM, et al. (2014). Cannabis and traffic collision risk: findings from a case-crossover study of injured drivers presenting to emergency departments. Int J Public Health. 59(2):395–404.

Berning A, Compton R, Wochinger K (2015). Results of the 2013-2014 National roadside survey of alcohol and drug use by drivers. Traffic Safety Facts Research Note, Report No. DOT HS 812 118. Washington (DC): National Highway Traffic Safety Administration.

Calabria B, Degenhardt L, Hall W, Lynskey M (2010b). Does cannabis use increase the risk of death? Systematic review of epidemiological evidence on adverse effects of cannabis use. Drug Alcohol Rev. 29:318–30.

Cherpitel CJ, Ye Y, Watters K, Brubacher JR, Strenstrom R (2012). Risk of injury from alcohol and drug use in the emergency department: a case-crossover study. Drug Alcohol Rev. 31(4):431–438.

Chesher G, Greeley J, Saunders J (1992). Tolerance to the effects of alcohol. In: Greeley J, Gladstone W, editors. The effects of alcohol on cognitive, psychomotor, and affective functioning. Kensington: National Drug and Alcohol Research Centre: 44–65.

Compton R, Berning A (2015). Drug and alcohol crash risk. Traffic Safety Facts Research Note, Report No. DOT HS 812 117. Washington (DC): National Highway Traffic Safety Administration.

Crean RD, Crane NA, Mason BJ (2011). An evidence based review of acute and long-term effects of cannabis use on executive cognitive functions. J Addict Med. 5(1):1–8.

Dines AM, Wood DM, Galicia M, Yates CM, Heyerdahl F, Hovda KE, et al. (2015). Presentations to the emergency department following cannabis use – a multi-centre case series from ten European countries. J Med Toxicol. 11(4):415-21.

Dubois S, Mullen N, Weaver B, Bédard M (2015). The combined effects of alcohol and cannabis on driving: impact on crash risk. Forensic Sci Int. 248: 94–100.

Elvik R (2015). Risk of road traffic injury associated with the use of drugs [background paper submitted to the WHO Technical Consultation on Drug Use and Road Safety, Geneva, Switzerland, 17-18 December 2014.

Fischer B, Imtiaz S, Rudzinski K, Rehm J (2015). Crude estimates of cannabis-attributable mortality and morbidity in Canada–implications for public health focused intervention priorities. J Public Health. doi:10.1093/pubmed/fdv005.

Gable RS (2004). Comparison of acute lethal toxicity of commonly abused psychoactive substances. Addiction. 99:686–96.

Gerberich S, Sidney S, Braun BL, Tekawa IS, Tolan KK, Quesenberry CP (2003). Marijuana use and injury events resulting in hospitalization. Ann epidemiol. 13(4):230–7.

Gmel G, Kuendig, H, Rehm J, Schreyer N, Daeppen JB (2009). Alcohol and cannabis use as risk factors for injury – a case-crossover analysis in a Swiss hospital emergency department. Biomed Central Public Health. 9:40.

Goldsmith RS, Targino MC, Fanciullo GJ, Martin DW, Hartenbaum NP, White JM, et al. (2015). Medical marijuana in the workplace: challenges and management options for occupational physicians. J Occup Environ Med. 57(5):518–25.

Hall W (2012). Driving while under the influence of cannabis (editorial). BMJ. 344:e595.

Hall WD, Solowij N, Lemon J (1994). The health and psychological consequences of cannabis use (vol. 25). Canberra: Australian Government Publishing Service.

Hartman RL, Huestis MA (2013). Cannabis effects on driving skills. Clin Chem. 59(3):478–92.

Hels T, Bernhoft IM, Lyckegaard A, Houwing S, Hagenzieker M, Legrand SA (2012). Risk of injury by driving with alcohol and other drugs. Revision 2.0 DRUID - Driving Under the Influence of Drugs, Alcohol and Medicines; sixth framework programme deliverable D2.3.5. Copenhagen: Danmarks Tekniske Universitet and partners for the European Commission.

Ilie G, Adlaf EM, Mann RE, Ialomiteanu A, Hamilton H, Rehm J, et al. (2015). Associations between a history of traumatic brain injuries and current cigarette smoking, substance use, and elevated psychological distress in a population sample of Canadian adults. J Neurotrauma. 32(14):1130–4.

Iversen L (2007). The science of marijuana, second edition. Oxford: Oxford University Press.

Iversen L (2012). How cannabis works in the human brain. In: Castle D, Murray R, D’Souza DC, editors. Marijuana and madness. Cambridge: Cambridge University Press:1–11.

Jouanjus E, Lapeyre-Mestre M, Micallef J (2014). Cannabis use: signal of increasing risk of serious cardiovascular disorders. J Am Heart Assoc. 3(2):e000638.

Lachenmeier DW, Rehm J (2015). Comparative risk assessment of alcohol, tobacco, cannabis and other illicit drugs using the margin of exposure approach. Sci Rep. 5:8126.

Laumon B, Gadegbeku B, Martin JL, Biecheler MB (2005). Cannabis intoxication and fatal road crashes in France: population based case-control study. BMJ. 331(7529):1371.

Leirer VO, Yesavage JA, Morrow DG (1991). Marijuana carry-over effects on aircraft pilot performance. Aviat Space Environ Med. 62(3):221–7.

Li MC, Brady JE, DiMaggio CJ, Lusardi AR, Tzong KY, Li G (2012). Marijuana use and motor vehicle crashes. Epidemiol Rev. 34(1):65–72.

Liakoni E, Dolder PC, Rentsch K, Liechti ME (2015). Acute health problems due to recreational drug use in patients presenting to an urban emergency department in Switzerland. Swiss Med Wkly. 145:w14166.

Macdonald S, Anglin-Bodrug K, Mann RE, Erickson P, Hathaway A, Chipman M, et al. (2003). Injury risk associated with cannabis and cocaine use. Drug Alcohol Depend. 72(2):99–115.

Mittleman MA, Lewis RA, Maclure M, Sherwood JB, Muller JE (2001). Triggering myocardial infarction by marijuana. Circulation. 103:2805–9.

Moskowitz H (1985). Marihuana and driving. Accid Anal Prev. 17(4):323–45.

Mura P, Kintz P, Ludes B, Gaulier JM, Marquet P, Martin-Dupont S, et al. (2003). Comparison of the prevalence of alcohol, cannabis and other drugs between 900 injured drivers and 900 control subjects: results of a French collaborative study. Forensic Sci Int. 133(1-2):79–85.

Pacher P, Kunos G (2013). Modulating the endocannabinoid system in human health and disease – successes and failures. FEBS J. 280(9):1918–43.

Phillips JA, Holland MG, Baldwin DD, Meuleveld LG, Mueller KL, Perkison B, et al. (2015). Marijuana in the workplace: guidance for occupational health professionals and employers: joint guidance statement of the American Association of Occupational Health Nurses and the American College of Occupational and Environmental Medicine. J Occup Environ Med. 57(4):45975.

Ranganathan M, D'Souza DC (2006). The acute effects of cannabinoids on memory in humans: a review. Psychopharmacology. 188(4):425–44.

Robbe HWJ, O’Hanlon JF (1993). Marijuana and actual driving performance. Report No. DOT HS 808 078. Washington (DC): National Highway Traffic Safety Administration.

Robbe HW (1994). Influence of marijuana on driving. Maastricht: Institute for Human Psychopharmacology.

SAMHSA (2012). Drug Abuse Warning Network (DAWN) 2010: national estimates of drug related emergency department visits. HHS publication no. (SMA)12-4733, DAWN series D-38. Rockville (MD): Substance Abuse and Mental Health Services Administration.

SAMHSA (2013). Drug Abuse Warning Network (DAWN) 2011: national estimates of drug related emergency department visits. HHS publication no. (SMA) 13-4760, DAWN Series D-39. Rockville (MD): Substance Abuse and Mental Health Services Administration.

Schmid K, Schönlebe J, Drexler H, Mueck-Weymann M (2010). The effects of cannabis on heart rate variability and well-being in young men. Pharmacopsychiatry. 43(4):147–50.Smiley A (1999). Marijuana: on road and driving simulator studies. In: Kalant H, Corrigall W, Hall WD, et al., editors. The health effects of cannabis. Toronto: Centre for Addiction and Mental Health:171–91.

Smith DE (1968). Acute and chronic toxicity of marijuana. J Psychedelic Drugs. 2:37–47.

Tashkin DP (2015). Does marijuana pose risks for chronic airflow obstruction? Ann Am Thorac Soc. 12(2):235–6.

Thomas H (1993). Psychiatric symptoms in cannabis users. Brit J Psychiat. 163:141–9.

Weil A (1970). Adverse reactions to marijuana, classification, and suggested treatment. NEJM. 282:997–1000.

WHO (1997). Cannabis: a health perspective and research agenda. Geneva: World Health Organization:46.


Chapter 6

Advisory Council on the Misuse of Drugs (2008). Cannabis: classification and public health. London: Home Office.

Agrawal A, Lynskey MT (2009). Tobacco and cannabis co-occurrence: does route of administration matter? Drug Alcohol Depend. 99(1–3):240–7.

Agrawal A, Nurnberger JI Jr., Lynskey MT (2011). Cannabis involvement in individuals with bipolar disorder. Psychiatry Res. 185(3):459–61.

Ajdacic-Gross V, Lauber C, Warnke I, Haker H, Murray RM, Rössler W (2007). Changing incidence of psychotic disorders among the young in Zurich. Schizophren Res. 95(1–3):9–18.

Allsop DJ, Copeland J, Lintzeris N, Dunlop AJ, Montebello M, Sadler C, et al. (2012). Quantifying the clinical significance of cannabis withdrawal. PLoS One. 7(9):e44864.

Allsop DJ, Copeland J, Lintzeris N, Dunlop AJ, Montebello M, Sadler C, et al. (2014). Nabiximols as an agonist replacement therapy during cannabis withdrawal: a randomized clinical trial. JAMA Psychiatry. 71(3):281–91.

Andréasson S, Allebeck P (1990). Cannabis and mortality among young men: a longitudinal study of Swedish conscripts. Scand J Soc Med. 18:9–15.

Andréasson S, Allebeck P, Engström A, Rydeberg U (1987). Cannabis and schizophrenia: a longitudinal study of Swedish conscripts. Lancet. 2(8574):1483–6.

Anthony JC (2006). The epidemiology of cannabis dependence. In: Roffman RA, Stephens RS, editors. Cannabis dependence: its nature, consequences and treatment. Cambridge: Cambridge University Press:58–105.

Arendt M, Munk-Jørgensen P, Sher L, Wallenstein Jensen SO (2013). Mortality following treatment for cannabis use disorders: predictors and causes. J Subst Abuse Treat. 44(4):400–6.

Arseneault L, Cannon M, Poulton R, Murray R, Caspi A, Moffitt TE (2002). Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. BMJ. 325(7374):1212–3.

Auer R, Vittinghoff E, Yaffe K, Künzi A, Kertesz SG, Levine DA, et al. (2016). Association between lifetime marijuana use and cognitive function in middle age: the Coronary Artery Risk Development in Young Adults (CARDIA) study. JAMA Intern Med. doi: 10.1001/jamainternalmed.2015.7841.

Bagge CL, Borges G (2015). The acute and chronic effects of cannabis on suicidal ideation, non fatal attempts, and death by suicide drugs [background paper submitted to the WHO Scientific Meeting on Harms to Health Due to Cannabis, Stockholm, 21–23 April 2015, available from the WHO Secretariat upon request].

Beautrais A, Joyce P, Mulder R (1999). Cannabis abuse and serious suicide attempts. Addiction. 94(8):1155–64.

Bergen SE, Gardner CO, Aggen SH, Kendler KS (2008). Socioeconomic status and social support following illicit drug use: causal pathways or common liability? Twin Res Hum Genet. 11(3):266–74.

Brook JS, Lee JY, Finch SJ, Seltzer N, Brook DW (2013). Adult work commitment, financial stability, and social environment as related to trajectories of marijuana use beginning in adolescence. Subst Abus. 34:298305.

Borges G, Bagge CL, Orozco R (2016). A literature review and meta-analyses of cannabis use and suicidality. J Affect Disord. 195:63–74.

Borowsky IW, Ireland M, Resnick MD (2001). Adolescent suicide attempts: risks and protectors. Pediatrics. 107(3):485–93.

Bovasso GB (2001). Cannabis abuse as a risk factor for depressive symptoms. Am J Psych. 158(12):2033–7.

Boydell J, van Os J, Caspi A, Kennedy N, Giouroukou E, Fearon P, et al. (2006). Trends in cannabis use prior to first presentation with schizophrenia, in South-East London between 1965 and 1999. Psychol Med. 36(10):1441–6.

Budney AJ, Hughes JR (2006). The cannabis withdrawal syndrome. Curr Opin Psychiatry. 19:233–8.

CDC (2006). Web-based injury statistics query and reporting system (WISQARS™). Atlanta (GA): Centers for Disease Control and Prevention (http://www.cdc.gov/ncipc/wisqars, accessed 05 September 2015).

Clarke MC, Coughlan H, Harley M, Connor D, Power E, Lynch F, et al. (2014). The impact of adolescent cannabis use, mood disorder and lack of education on attempted suicide in young adulthood. World Psychiatry. 13(3):322–3.

Crane NA, Schuster RM, Fusar-Poli P, Gonzales, R (2013). Effects of cannabis on neurocognitive functioning: recent advances, neurodevelopmental influences, and sex differences. Neuropsychol Rev. 23(2):117–37.

Darke S, Duflou J, Torok M (2009). Drugs and violent death: comparative toxicology of homicide and non-substance toxicity suicide victims. Addiction. 104(6):1000–5.

Degenhardt L, Dierker L, Chiu WT, Medina-Mora, ME, Neumark Y, Sampson N, et al. (2010). Evaluating the drug use "gateway" theory using cross-national data: consistency and associations of the order of initiation of drug use among participants in the WHO World Mental Health Surveys. Drug Alcohol Depend. 108(1-2):84–97.

Degenhardt L, Hall WD (2012). Extent of illicit drug use and dependence, and their contribution to the global burden of disease. Lancet. 379(9810):55–70.

Di Forti M, Morgan C, Dazzan P, Pariante C, Mondelli V, Reis Marques T, et al. (2009). High-potency cannabis and the risk of psychosis. Brit J Psychiat. 195(6):488–91.

Di Forti M, Sallis H, Allegri F, Trotta A, Ferraro L, Stilo SA, et al. (2014). Daily use, especially of high-potency cannabis, drives the earlier onset of psychosis in cannabis users. Schizophr Bull. 40(6):1509–17.

Di Forti M, Marconi A, Carra E, Fraietta S, Trotta A, Bonomo M, et al. (2015). Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: a case-control study. Lancet Psychiatry. 2(3):233–8.

D'Souza DC, Perry E, Macdougall L, Ammerman Y, Cooper T, Wu YT, et al. (2004). The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology. 29(8):1558–72.

D’Souza DC, Abi-Saab WM, Madonick S, Forselius-Bielen K, Doersch A, Braley G, et al (2005). Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addition. Biol Psychiatry. 57:594–608.

D'Souza DC, Sewell RA, Ranganathan M (2009). Cannabis and psychosis/schizophrenia: human studies. Eur Arch Psychiatry Clin Neurosci. 259(7):413-31.

Ellgren M, Spano SM, Hurd YL (2007) Adolescent cannabis exposure alters opiate intake and opioid limbic neuronal populations in adult rats. Neuropsychopharmacology. 32(3):607–15.

Ellgren M, Artmann A, Tkalych O, Gupta A, Hansen HS, Hansen SH, et al. (2008) Dynamic changes of the endogenous cannabinoid and opioid mesocorticolimbic systems during adolescence: THC effects. Eur Neuropsychopharmacol. 18(11):826–34.

Ellickson P, Bui K, Bell R, McGuigan KA (1998). Does early drug use increase the risk of dropping out of high school? J Drug Issues. 28(2):357–380.

EMCDDA (2011). Table TDI-105, part vii: all clients entering inpatient treatment by primary drug and age, 2009 or most recent year available: all cannabis inpatient clients by country and age. Statistical Bulletin 2011: Demand for Treatment (TDI). Lisbon: European Monitoring Centre for Drugs and Drug Addiction.

EMCDDA (2013). Drug treatment overview for Netherlands. Lisbon: European Monitoring Centre for Drugs and Drug Addiction (http://www.webcitation.org/6S4yjPY59, accessed 15 June 15 2015).

Feingold D, Weiser M, Rehm J, Lev-Ran S (2015). The association between cannabis use and mood disorders: a longitudinal study. J Affect Disord. 172:2118.

Fergusson DM, Horwood L (1997). Early onset cannabis use and psychosocial adjustment in young adults. Addiction. 92(3):27996.

Fergusson DM, Lynskey MT, Horwood LJ (1996). The short-term consequences of early onset cannabis use. J Abnorm Child Psych. 24(4):499–512.

Fergusson DM, Horwood LJ, Swain-Campbell NR (2003). Cannabis dependence and psychotic symptoms in young people. Psychol Med. 33:15–21.

Fergusson D, Boden J, Horwood L (2006). Cannabis use and other illicit drug use: testing the cannabis gateway hypothesis. Addiction. 101(4):55669.

Fergusson D, Boden J, Horwood L (2008). The developmental antecedents of illicit drug use: evidence from a 25-year longitudinal study. Drug Alcohol Depend. 96(12):16577.

Fergusson DM, Boden JM (2008) Cannabis use and later life outcomes. Addiction. 103(6):96976.

Fergusson DM, Boden JM, Horwood LJ (2015) Psychosocial sequelae of cannabis use and implications for policy: findings from the Christchurch Health and Development Study. Soc Psychiatry Psychiatr Epidemiol. 50(9): 131726.

Fergusson D, Horwood L, Swain-Campbell N (2003). Cannabis dependence and psychotic symptoms in young people. Psychol Med. 33:15–21.

Fischer B, Imtiaz S, Rudzinski K, Rehm J (2015). Crude estimates of cannabis-attributable mortality and morbidity in Canada–implications for public health focused intervention priorities. J Pub Health. doi:10.1093/pubmed/fdv005 (Epub ahead of print ).

Florez-Salamanca L, Secades-Villa R, Budney AJ, Garcia-Rodriguez O, Wang S, Blanco C (2013) Probability and predictors of cannabis use disorders relapse: results of the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). Drug Alcohol Depend. 132(1-2):127-33 (http://dx.doi.org/10.1016/j.drugalcdep, accessed 05 September 2015).

Gage SH, Zammit S, Hickman M (2013). Stronger evidence is needed before accepting that cannabis plays an important role in the aetiology of schizophrenia in the population. F1000 Medicine Reports. 5:2.

Giordano GN, Ohlsson H, Sundquist K, Sunquist J, Kendler K (2014). The association between cannabis abuse and subsequent schizophrenia: a Swedish national co-relative control study. Psychol Med. 45(2):407–414.

Goodman M, George T (2015). Is there a link between cannabis and mental illness? In: George T, Vaccarino F, editors. Substance abuse in Canada: the effects of cannabis use during adolescence. Ottawa: Canadian Centre on Substance Abuse:3247.

Grant I, Gonzalez R, Carey CL, Natarajan L, Wolfson T (2003). Non-acute (residual) neurocognitive effects of cannabis use: a meta-analytic study. J Int Neuropsychol Soc. 9(5):679–89.

Grant JD, Lynskey MT, Scherrer JF, Agrawal A, Heath AC, Bucholz KK (2010). A cotwin-control analysis of drug use and abuse/dependence risk associated with early-onset cannabis use. Addict Behav. 35:35–41.

Grant JD, Scherrer JF, Lynskey MT, Agrawal A, Duncan AE, Haber JR, et al. (2012). Associations of alcohol, nicotine, cannabis, and drug use/dependence with educational attainment: evidence from cotwin-control analyses. Alcohol Clin Exp Res. 36(8):1412–20.

Hall W, Degenhardt L, Teesson M (2009). Understanding comorbidity between substance use, anxiety and affective disorders: broadening the research base. Addict Behav. 34:526–30.

Hall WD, Lynskey M (2005). Is cannabis a gateway drug? Testing hypotheses about the relationship between cannabis use and the use of other illicit drugs. Drug Alcohol Rev. 24(1):39–48.

Hall W (2014). What has research over the past two decades revealed about the adverse health effects of recreational cannabis use? Soc Study Addict. 110:19–35.

Hall WD, Pacula RL (2010). Cannabis use and dependence: public health and public policy (reissue of first edition 2003). Cambridge: Cambridge University Press.

Hall WD, Solowij N, Lemon J (1994). The health and psychological consequences of cannabis use (vol. 25). Canberra: Australian Government Publishing Service.

Haney M, Evins AE (2016). Does cannabis cause, exacerbate or ameliorate psychiatric disorders? An oversimplified debate discussed. Neuropsychopharmacology. 41(2):393–401.

Hasin, D, Tulshi D, Kerridge B, Goldstein R, Chou P, Zhang H, et al. (2015) Prevalence of marijuana use disorders in the United States between 2001-2002 and 2012-2013. JAMA Psychiatry. 72(12):1235–42. doi:10.1001/jamapsychiatry.2015.1858.

Henquet C, Krabbendam L, Spauwen J, Kaplan C, Lieb R, Wittchen HW, et al. (2004). Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people. British Medical Journal. 330(7481):11.

Henquet C, Krabbendam L, de Graaf R, ten Have M, van Os J (2006). Cannabis use and expression of mania in the general population. Journal of Affective Disorders. 95(1-3):103–110.

Hibell B, Guttormsson U, Ahlström S, Balakireva O, Bjarnason T, Kokkevi A (2012). The 2011 ESPAD report: substance use among students in 36 European countries (http://www.espad.org/Uploads/ESPAD_reports/2011). Stockholm: the Swedish Council for Information on Alcohol and Other Drugs (CAN).

Hickman M, Vickerman P, Macleod J, Kirkbride J, Jones PB (2007). Cannabis and schizophrenia: model projections of the impact of the rise in cannabis use on historical and future trends in schizophrenia in England and Wales. Addiction. 102(4):597–606.

Horwood LJ, Fergusson DM, Hayatbakhsh MR, Najman JM, Coffey C, Patton GC, et al. (2010). Cannabis use and educational achievement: findings from three Australasian cohort studies. Drug Alcohol Depend. 110(3):247–53.

Horwood LJ, Fergusson DM, Coffey C, Patton GC, Tait R, Smart D, et al. (2012). Cannabis and depression: an integrative data analysis of four Australasian cohorts. Drug Alcohol Depend. 126(3):369–78.

Johnston LD, O'Malley PM, Bachman JG, Schulenberg JE (2010). Marijuana use is rising; ecstasy use is beginning to rise; and alcohol use is declining among U.S. teens. Press release. Ann Arbor (MI): University of Michigan News Service (http://www.monitoringthefuture.org/pressreleases/10drugpr_complete.pdf, accessed 11 February 2016).

Jorquera N, Alvarado R, Libuy N, de Angel V (2015). Association between unmet needs and clinical status in patients with first episode of schizophrenia in Chile. Front Psychiatry. 6(57). doi: 10.3389/fpsyt.2015.00057.

Juon HS, Ensminger ME (1997). Childhood, adolescent, and young adult predictors of suicidal behaviors: a prospective study of African Americans. J Child Psychol. 38(5):553–63.

Kandel D (2002). Stages and pathways of drug involvement: examining the gateway hypothesis. New York: Cambridge University Press.

Kung HC, Pearson JL, Liu X. (2003). Risk factors for male and female suicide decedents ages 15-64 in the United States. Results from the 1993 National Mortality Followback Survey. Soc Psychiatry Psychiatr Epidemiol. 38(8):419–26.

Kung HC, Pearson JL, Wei R (2005). Substance use, firearm availability, depressive symptoms, and mental health service utilization among white and African American suicide decedents aged 15 to 64 years. Ann epidemiol. 15(8):614–21.

Lai H, Sitharthan T (2012). Exploration of the comorbidity of cannabis use disorders and mental health disorders among inpatients presenting to all hospitals in New South Wales, Australia. Am J Drug Alcohol Abuse. 38(6):567–74.

Lessem J, Hopfer CJ, Haberstick BC, Timberlake D, Ehringer MA, Smolen A, et al. (2006). Relationship between adolescent marijuana use and young adult illicit drug use. Behav Genet. 36(4):498–506.

Lev-Ran S, Le Foll B, McKenzie K, George TP, Rehm J (2013). Bipolar disorder and co-occurring cannabis use disorders: characteristics, co-morbidities and clinical correlates. Psychiatry Res. 209(3):459–65.

Lorenzetti V, Lubman DI, Fornito A, Whittle S, Takagi MJ, Solowij N, et al. (2013). The impact of regular cannabis use on the human brain: a review of structural neuroimaging studies. In: Miller PM, editor. Biological research on addiction. San Diego (CA): Academic Press: 711–28.

Lichtman A, Martin B (2005). Cannabinoid tolerance and dependence. Handbook of Experimental Pharmacology. 168:691–717.

Lynskey M, Hall W (2000). The effects of adolescent cannabis use on educational attainment: a review. Addiction. 95(11):1621–30.

Lynskey MT, Heath AC, Bucholz KK, Slutske WS, Madden PAF, Nelson EC, et al. (2003). Escalation of drug use in early-onset cannabis users vs co-twin controls. JAMA. 289(4):427–33.

Lynskey MT, Vink JM, Boomsma DI (2006). Early onset cannabis use and progression to other drug use in a sample of Dutch twins. Behav Genet. 36(2):195–200.

Manrique-Garcia E, Zamit S, Dalman C, Hemmingsson T, Allebeck P (2012). Cannabis use and depression: a longitudinal study of a national cohort of Swedish conscripts. BMC Psychiatry. 12(112). doi:10.1186/1471-244X-12-112.

McGee R, Williams S, Nada-Raja S (2005). Is cigarette smoking associated with suicidal ideation among young people? Am J Psych. 162(3):619–20.

McGrath J, Welham J, Scott J, Varghese D, Degenhardt L, Hayatbakhsh MR, et al. (2010). Association between cannabis use and psychosis-related outcomes using sibling pair analysis in a cohort of young adults. Arch Gen Psychiatry. 67(5):440–47.

Meier MH, Caspi A, Ambler A, Harrington H, Houts R, Keefe RS, et al. (2012). Persistent cannabis users show neuropsychological decline from childhood to midlife. Proc Natl Acad Sci U S A. 109(40):E2657–64.

Moffitt TE, Meier MH, Caspi A, Poulton R (2013). Reply to Rogeberg & Daly: no evidence that socioeconomic status or personality differences confound the association between cannabis use and IQ decline. Proc Natl Acad Sci U S A. 110(11):E980–2.

Moore T, Zammit S, Lingford-Hughes A, Barnes TRE, Jones PB, Burke M, et al. (2007). Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet. 370(9584):319–28.

Morral A, McCaffrey D, Paddock S (2002). Reassessing the marijuana gateway effect. Addiction. 97(12):1493–504.

Morrison PD, Zois V, Mckeown DA, Lee TD, Holt DW, Powell JF, et al. (2009). The acute effects of synthetic intravenous delta9-tetrahydrocannabinol on psychosis, mood and cognitive functioning. Psychol Med. 39(10):1607–16.

Moussavi S, Chatterji S, Verdes E, Tandon A, Patel V, Ustun B (2007). Depression, chornic diseases, and decrements in health: results from the World Health Surveys. Lancet. 370(9590):851–8.

Murray RM, Paparelli A, Morrison PD, Marconi A, Di Forti M (2013). What can we learn about schizophrenia from studying the human model, drug-induced psychosis? Am J Med Genet B Neuropsychiatr Genet. 162B:661–70.

Myles H, Myles N, Large M (2015). Cananbis use in first episode psychosis: meta-analysis of prevalence, and the time course of initiation and continued use. Australasian and NZ J of Psychiatry. doi: 10.1177/0004867415599846 (Epub ahead of print).

Newcomb MD, Scheier LM, Bentler PM (1993). Effects of adolescent drug use on adult mental health: a prospective study of a community sample. Exp Clin Psychopharm. 1(1-4):215–41.

Newcomb MD, Vargas-Carmona J, Galaif ER (1999). Drug problems and psychological distress among a community sample of adults: predictors, consequences, or confound? J Community Psychol. 27(4):405–29.

Patton GC, Coffey C, Carlin JB, Sawyer SM, Lynskey M (2005). Reverse gateways? Frequent cannabis use as a predictor of tobacco initiation and nicotine dependence. Addiction. 100(10):1518–25.

Pedersen W (2008). Does cannabis use lead to depression and suicidal behaviours? A population-based longitudinal study. Acta Psychiatrica Scandinavica. 118(5):395–403.

Petronis KR, Samuels JF, Moscicki EK, Anthony JC (1990). An epidemiologic investigation of potential risk factors for suicide attempts. Soc Psychiatry Psychiatr Epidemiol. 25(4):193–9.

Palacio C, Garcia J, Diago J, Zapata C, Lopez G, Ortiz J, et al. (2007) Identification of suicide risk factors in Medellin Colombia: a case-control study of psychological autopsy in a developing country. Arch Suicide Res. 11(3):297–308.

Power RA, Verweij KJH, Zuhair M, Montgomery GW, Henders AK, Heath AC, et al. (2014). Genetic predisposition to schizophrenia associated with increased use of cannabis. Molecular Psychiatry. 19(11):1201–4.

Price C, Hemmingsson T, Lewis G, Zammit S, Allebeck P (2009). Cannabis and suicide: longitudinal study. Brit J Psychiat. 195(6):492–7.

Roxburgh A, Hall WD, Degenhardt L, McLaren J, Black E, Copeland J, et al. (2010). The epidemiology of cannabis use and cannabis-related harm in Australia 1993-2007. Addiction. 105(6):1071–9.

Rogeberg O (2013). Correlations between cannabis use and IQ change in the Dunedin cohort are consistent with confounding from socioeconomic status. Proc Natl Acad Sci U S A. 110(11):4251–4.

Schizophrenia Working Group of the Psychiatric Genomics Consortium (2014). Biological insights from 108 schizophrenia associated genetic loci. Nature. 511:421–427.

Schreiner A, Dunne ME (2012). Residual effects of cannabis use on neurocognitive performance after prolonged abstinence: a meta-analysis. Exp Clin Psychopharmacol. 20:420–9.

Sheehan CM, Rogers RJ, Williams GW, Boardman JD (2013). Gender differences in the presence of drugs in violent deaths. Addiction. 108(3):547–55.

Shields LB, Hunsaker DM, Hunsaker JC III, Ward MK (2006). Toxicologic findings in suicide: a 10-year retrospective review of Kentucky medical examiner cases. Am J Forensic Med Pathol 27(2):106–12.

Silberberg C, Castle D, Koethe D (2012). Cannabis, cannabinoids, and bipolar disorder. In: Castle D, Murray R, D’Souza DC, editors. Marijuana and madness, second edition. New York (NY): Cambridge University Press:129–36.

Silins E, Horwood LJ, Patton GC, Fergusson DM, Olsson CA, Hutchinson DM, et al. (2014). Young adult sequelae of adolescent cannabis use: an integrative analysis. Lancet Psychiatry. 1(4):286–93.

Solowij N (2002). Cannabis and cognitive functioning. In: Onaivi ES, editor. Biology of marijuana: from gene to behaviour. London: Taylor & Francis.

Solowij N, Battisti R (2008). The chronic effects of cannabis on memory in humans: a review. Curr Drug Abuse Rev. 1(1):81–98.

Solowij N, Jones KA, Rozman ME, Davis SM, Ciarrochi J, Heaven PCL, et al. (2011). Verbal learning and memory in adolescent cannabis users, alcohol users and non-users. Psychopharmacology. 216(1):131–44.

Solowij N, Pesa N (2012). Cannabis and cognition: short and long term effects. In: Castle D, Murray R, D’Souza DC, editors. Marijuana and madness, second edition. New York (NY): Cambridge University Press:91–102.

Stefanis NC, Dragovic M, Power BD, Jablensky A, Castle D, Morgan VA (2014). The effect of drug use on the age at onset of psychotic disorders in an Australian cohort. Schizophr Res. 156: 211–6.

Swift W, Hall W, Teesson, M (2001) Cannabis use and dependence among Australian adults: results from the National Survey of Mental Health and Well-being. Addiction. 96: 737–48.

Swift W, Coffey C, Degenhardt L, Carlin JB, Romaniuk H, Patton GC (2012). Cannabis and progression to other substance use in young adults: findings from a 13-year prospective population-based study. J Epidemiol Commun H 66(7):e26.

Therapeutic Goods Administration (2013). Australian public assessment report for Nabiximols: proprietary product name: Sativex. Sponsor: Novartis Pharmaceuticals Australia Pty Limited. Canberra: Commonwealth of Australia.

Tomasiewicz HC, Jacobs MM, Wilkinson MB, Wilson SP, Nestler EJ, Hurd YL (2012). Proenkephalin mediates the enduring effects of adolescent cannabis exposure associated with adult opiate vulnerability. Biol Psychiatry. 72(10):803–10.

Ustün TB, Ayuso-Mateos JL, Chatterji S, Mathers C, Murray CJ (2004). Global burden of depressive disorders in the year 2000. Brit J Psychiat. 184:386–92.

van der Pol P, Liebregts N, de Graaf R, Korf DJ, van den Brink W, van Laar M (2013). Predicting the transition from frequent cannabis use to cannabis dependence: a three-year prospective study. Drug Alcohol Depend. 133(2):352-9. doi:10.1016/j.drugalcdep.2013.06.009.

van Os J, Bak M, Hanssen M, Bijl RV, De Graaf R, Verdoux H. (2002). Cannabis use and psychosis: a longitudinal population-based study. Am J Epidemiol. 156(4):319–27.

van Ours JC, Williams J, Fergusson D, Horwood LJ (2013). Cannabis use and suicidal ideation. J Health Econ. 32(3):524–37.

Verweij KJH, Huizink AC, Agrawal A, Martin NG, Lynskey MT (2013). Is the relationship between early-onset cannabis use and educational attainment causal or due to common liability? Drug Alcohol Depend. 133(2):580-6. doi:10.1016/j.drugalcdep.2013.07.034.

Wagner F, Anthony J (2002). Into the world of illegal drug use: Exposure opportunity and other mechanisms linking the use of alcohol, tobacco, marijuana, and cocaine. Am J Epidemiol. 155(10):918–25.

Wichstrom L (2000). Predictors of adolescent suicide attempts: a nationally representative longitudinal study of Norwegian adolescents. J Acad Child Psy. 39(5):603–10.

WHO (1992). The ICD-10 classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines. Geneva: World Health Organization.

Wilcox HC, Anthony JC (2004). The development of suicide ideation and attempts: an epidemiologic study of first graders followed into young adulthood. Drug Alcohol Depend. 76 Suppl:S53–67.

Yücel M, Solowij N, Respondek C, Whittle S, Fornito A, Pantellis C, et al. (2008). Regional brain abnormalities associated with long-term heavy cannabis use. Arch Gen Psychiatry. 65:694–701.

Zammit S, Allebeck P, Andreasson S, Lundberg I, Lewis G (2002). Self-reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study. BMJ. 325(7374):1199–201.

Zhang X, Wu LT (2014). Suicidal ideation and substance use among adolescents and young adults: a bidirectional relation? Drug Alcohol Depend. 142:63–73.


Chapter 7

Aldington S, Williams M, Nowitz M, Weatherall M, Pritchard A, Mcnaughton A, et al. (2007). Effects of cannabis on pulmonary structure, function and symptoms. Thorax. 62(12):1058–63.

Aldington S, Harwood M, Cox B, Weatherall M, Beckert L, Hansell A, et al. (2008a). Cannabis use and cancer of the head and neck: case-control study. JAMA Otolaryngol Head Neck Surg. 138(3):374–80.

Aldington S, Harwood M, Cox B, Weatherall M, Beckert L, Hansell A, et al. (2008b). Cannabis use and risk of lung cancer: a case-control study. Eur Respir J. 31(2):280–6.

Aronow WS, Cassidy J (1974). Effect of marijuana and placebo-marijuana smoking on Angina Pectoris. NEJM. 291:65–7.

Arora S, Goyal H, Aggarwal P, Kukar A (2012). ST-segment elevation myocardial infarction in a 37-year-old man with normal coronaries – it is not always cocaine! Am J Emerg Med 30(9):2091.e3-5.

Bailly C, Merceron O, Hammoudi N, Dorent R, Michel PL (2010). Cannabis induced acute coronary syndrome in a young female. Int J Cardiol. 143(1):e4-6.

Baldwin GC, Tashkin DP, Buckley DM, Park AN, Dubinett SM, Roth MD (1997) Marijuana and cocaine impair alveolar macrophage function and cytokine production. Am J Respir Crit Care Med. 156(5):1606–13.

Barber PA, Pridmore HM, Krishnamurthy V, Roberts S, Spriggs DA, Carter KN, et al. (2013). Cannabis, ischemic stroke, and transient ischemic attack: a case-control study. Stroke, 44(8):2327–9.

Basnet S, Mander G, Nicolas R (2009). Coronary vasposasm in an adolescent resulting from marijuana use. Pediatr Cardiol. 30(4):543–5.

Benson-Leung ME, Leung LY, Kumar S (2014). Synthetic cannabis and acute ischemic stroke. J Stroke Cerebrovasc Dis. 23(5):1239–41.

Berthiller J, Straif K, Boniol M, Voirin N, Benhaïm-Luzon V, Ayoub WB, et al. (2008). Cannabis smoking and risk of lung cancer in men: a pooled analysis of three studies in Maghreb. J Thorac Oncol. 3(12):1398–403.

Bloom JW, Kaltenborn WT, Paoletti P, Camilli A, Lebowitz MD (1987). Respiratory effects of non-tobacco cigarettes. BMJ. 295:1516–8.

Callaghan RC, Allebeck P, Sidorchuk A (2013). Marijuana use and risk of lung cancer: a 40-year cohort study. Cancer Causes Control. 24(10):1811–20.

Canga Y, Osmonov D, Karatas MB, Durmus G, Ilhan E, Kirbas V (2011). Cannabis: a rare trigger of premature myocardial infarction. Anadolu Kardiyol Derg [The Anatolian Journal of Cardiology]. 11(3):272–4.

Casier I, Vanduynhoven P, Haine S, Vrints C, Jorens PG (2013). Is recent cannabis use associated with acute coronary syndromes? Acta Cardiol. 69(2):131–6.

Chesher G, Hall W (1999). Effects of cannabis on the cardiovascular and gastrointestinal systems. In: Kalant H, Corrigall W, Hall WD, et al., editors. The health effects of cannabis. Toronto: Centre for Addiction and Mental Health:435–58.

Daling JR, Doody DR, Sun X, Trabert BL, Weiss NS, Chen C, et al. (2009). Association of marijuana use and the incidence of testicular germ cell tumors. Cancer. 115(6):1215–23.

Desbois AC, Cacoub P (2013). Cannabis-associated arterial disease. Ann Vasc Surg. 27(7):996–1005.

Deharo P, Massoure PL, Fourcade L (2013). Exercise-induced acute coronary syndrome in a 24-year-old man with massive cannabis consumption. Acta Cardiol. 68(4):425–8.

Duchene C, Olindo S, Chausson N, Jeannin S, Cohen-Tenoudji P, Smadja D (2010). Cannabis-induced cerebral and myocardial infarction in a young woman. Rev Neurol. 166:438–42.

Feng BJ, Ben-Ayoub W, Dahmoul S, Ayad M, Maachi F, Bedadra W, et al. (2009). Cannabis, tobacco and domestic fumes intake are associated with nasopharyngeal carcinoma in North Africa. Br J Cancer. 101(7):1207–12.

Fligiel SE, Roth MD, Kleerup EC, Barsky SH, Simmons MS, Tashkin DP (1997). Tracheobronchial histopathology in habitual smokers of cocaine, marijuana, and/or tobacco. Chest. 112(2):319–26.

Freeman MJ, Rose DZ, Myers MA, Gooch CL, Bozeman AC, Burgin WS (2013). Ischemic stroke after use of the synthetic marijuana "spice”. Neurology. 81(24):2090–3.

Frost L, Mostofsky E, Rosenbloom JI, Mukamal KJ, Mittleman MA (2013). Marijuana use and long-term mortality among survivors of acute myocardial infarction. Am Heart J. 165(2):170–5.

Gillison ML, D’Souza G, Westra W, Sugar E, Xiao W, Begum S, et al. (2008). Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst. 100(6):407–20.

Gottschalk L, Aronow W, Prakash R (1977). Effect of marijuana and placebo-marijuana smoking on psychological state and on psychophysiological and cardiovascular functioning in angina patients. Biol Psychiatry. 12(2):255–66.

Grufferman S, Schwartz AG, Ruyman FB, Maurer HM (1993). Parents' use of cocaine and marijuana and increased risk of rhabdomyosarcoma in their children. Cancer Causes Control. 4(3):217–24.

Gurney J, Young J, Roffers S, Smith MA, Bunin C (2000). Soft tissue sarcomas. In: Reis L, Eisner M, Kosary C, et al., editors. SEER Cancer Statistics Review, 1973–1997. Bethesda: National Cancer Institute:11–123.

Gurney J, Shaw C, Stanley J, Signal V, Sarfati D (2015) Cannabis exposure and risk of testicular cancer: a systematic review and meta-analysis. BMC Cancer. 15:897. doi: 10.1186/s12885-015-1905-6.

Hackam DG (2015). Cannabis and stroke. Stroke. 46:852–6.

Hall W, Macphee D (2002). Cannabis use and cancer. Addiction. 97:243–47.

Hancox RJ, Poulton R, Ely M, Welch D, Taylor DR, McLachlan CR, et al. (2010). Effects of cannabis on lung function: a population-based cohort study. Eur Respir J. 35(1):42–7.

Hancox RJ, Shin HH, Gray AR, Poulton R, Searson MR (2015). Effects of quitting cannabis on respiratory symptoms. Eur Respir J. 46(1):80–7.

Hashibe M, Morgenstern H, Cui Y, Tashkin DP, Zhang ZF, Cozen W, et al. (2006). Marijuana use and the risk of lung and upper aerodigestive tract cancers: results of a population-based case-control study. Cancer Epidemiol Biomarkers Prev. 15(10):1829–34.

Hashibe M, Straif K, Tashkin DP, Morgenstern H, Greenland S, Zhang ZF (2005). Epidemiologic review of marijuana use and cancer risk. Alcohol. 35(3):265–75.

Hii S, Tam JDC, Thompson BR, Naughton MT (2008). Bullous lung disease due to marijuana. Respirology. 13:122–7.

Hodcroft CJ, Rossiter MC, Buch AN (2014). Cannabis-associated myocardial infarction in a young man with normal coronary arteries. J Emerg Med. 47(3):277–81.

Johnson MK, Smith RP, Morrison D, Laszlo G, White RJ (2000). Large lung bullae in marijuana smokers. Thorax. 55:340–2.

Jones RT (2002). Cardiovascular system effects of marijuana. J Clin Pharmacol. 42(11):58S–63S.

Jouanjus E, Lapeyre-Mestre M, Micallef J (2014). Cannabis use: signal of increasing risk of serious cardiovascular disorders. J Am Heart Assoc. 3(2):e000638.

Jouanjus E, Leymarie F, Tubery M, Lapeyre-mestre M (2011). Cannabis-related hospitalizations: unexpected serious events identified through hospital databases. Brit J Clin Pharmaco. 71(5):758–65.

Jouanjus E, Pourcel L, Saivin S, Molinier L, Lapeyre-mestre M (2012). Use of multiple sources and capture-recapture method to estimate the frequency of hospitalizations related to drug abuse. Pharmacoepidemiol Drug Saf. 21(7):733–41.

Joy JE, Watson SJ, Benson JA, editors. Marijuana and medicine: assessing the science base. Washington (DC): The National Academies Press (http://iom.edu/Reports/2003/Marijuana-and-Medicine-Assessing-the-Science-Base.aspx, accessed 05 September 2015).

Kagen SL, Kurup VP, Sohnle PC, Fink JN (1983). Marijuana smoking and fungal sensitization. J Allergy Clin Immunol. 71:389–93.

Karabulut A, Cakmak M (2010). ST segment elevation myocardial infarction due to slow coronary flow occurring after cannabis consumption. Kardiol Pol [Polish Heart Journal]. 68(11):1266–8.

Kempker JA, Honig EG, Martin GS (2015). The effects of marijuana exposure on expiratory airflow. A study of adults who participated in the U.S. National Health and Nutrition Examination Study. Ann Am Thorac Soc. 12(2):135–141.

Kocabay G, Yildiz M, Duran NE, Ozkan M (2009). Acute inferior myocardial infarction due to cannabis smoking in a young man. J Cardiovasc Med. 10:669–70.

Kuijten RR, Bunin GR, Nass CC, Meadows AT (1992). Parental occupation and childhood astrocytoma: results of a case control study. Cancer Res. 52(4):782–6.

Lacson JCA, Carroll JD, Tuazon E, Castelao EJ, Bernstein L, Cortessis VK (2012). Population-based case-control study of recreational drug use and testis cancer risk confirms an association between marijuana use and nonseminoma risk. Cancer. 118(21):5374–83.

Leuchtenberger C (1983). Effects of marihuana (cannabis) smoke on cellular biochemistry of in vitro test systems. In: Fehr K, Kalant H, editors Cannabis and health hazards. Toronto: Addiction Research Foundation.

Liang C, Mcclean MD, Marsit C, Christensen B, Peters E, Nelson H, et al. (2009). A population-based case-control study of marijuana use and head and neck squamous cell carcinoma. Cancer Prev Res. 2(8):759–68.

Llewellyn CD, Johnson NW, Warnakulasuriya KA (2004). Risk factors for oral cancer in newly diagnosed patients aged 45 years and younger: a case-control study in Southern England. J Oral Pathol Med. 33(9):525–32.

Llewellyn CD, Linklater K, Bell J, Johnson NW, Warnakulasuriya S (2004). An analysis of risk factors for oral cancer in young people: a case-control study. Oral Oncol. 40(3):304–13.

MacPhee D (1999). Effects of marijuana on cell nuclei: a review of the literature relating to the genotoxicity of cannabis. In: Kalant H, Corrigall W, Hall WD, et al., editors. The health effects of cannabis. Toronto: Centre for Addiction and Mental Health:435–58.

Marks MA, Chaturvedi AK, Kelsey K, Straif K, Berthiller J, Schwartz SM, et al. (2014). Association of marijuana smoking with oropharyngeal and oral tongue cancers: pooled analysis from the INHANCE consortium. Cancer Epidemiol Biomarkers Prev. 23(1):160–71.

Marselos M, Karamanakos P (1999). Mutagenicity, developmental toxicity and carcinogeneity of cannabis. Addict Biol. 4(1):5–12.

Mehra R, Serebriiskii IG, Dunbrack RL, Robinson MK, Burtness B, Golemis EA (2006). The association between marijuana smoking and lung cancer: a systematic review. Arch Intern Med. 166(13):1359–67.

Mittleman MA, Lewis RA, Maclure M, Sherwood JB, Muller JE (2001). Triggering myocardial infarction by marijuana. Circulation. 103:2805–9.

Mittleman MA, Mintzer D, Maclure M, Tofler GH, Sherwood JB, Muller JE (1999). Triggering myocardial infarction by cocaine. Circulation. 99(21):2737–41.

Montecucco F, Di Marzo V (2012). At the heart of the matter: the endocannabinoid system in cardiovascular function and dysfunction. Trends Pharmacol Sci. 33(6):331–40.

Moore BA, Augustson EM, Moser RP, Budney AJ (2005). Respiratory effects of marijuana and tobacco use in a U.S. sample. J Gen Intern Med. 20(1):33–7.

Mukamal KJ, Maclure M, Muller JE, Mittleman MA (2008). An exploratory prospective study of marijuana use and mortality following acute myocardial infarction. Am Heart J. 155(3):465–70.

Phan TD, Lau KKP, Li X (2005). Lung bullae and pulmonary fibrosis associated with marijuana smoking. Australas Radiol. 49:411–4.

Pletcher MJ, Vittinghoff E, Kalhan R, Richman J, Safford M, Sidney S, et al. (2012). Association between marijuana exposure and pulmonary function over 20 years. JAMA. 307(2):173–81.

Pratap B, Korniyenko A (2012). Toxic effects of marijuana on the cardiovascular system. Cardiovasc Toxicol. 12:143–8.

Reis L, Eisner M, Kosary C, Hankey B, Miller B, Clegg L, et al., editors (2000). SEER cancer statistics review, 1973–1997. Bethesda: National Cancer Institute.

Renard D, Taieb G, Gras-Combe G, Labauge P (2012). Cannabis-related myocardial infarction and cardioembolic stroke. J Stroke Cerebrovasc Dis. 21:82–3.

Robinson L, Buckley J, Daigle A, Wells R, Benjamin D, Arthur D, et al. (1989). Maternal drug use and the risk of childhood nonlymphoblastic leukemia among offspring: an epidemiologic investigation implicating marijuana. Cancer. 63:1904–11.

Rosenblatt KA, Daling JR, Chen C, Sherman KJ, Schwarts SM (2004). Marijuana use and risk of oral squamous cell carcinoma. Cancer Res. 64(11):4049–54.

Roth MD, Arora A, Barsky SH, Kleerup EC, Simmons M, Tashkin DP. (1998). Airway inflammation in young marijuana and tobacco smokers. Am J Respir Crit Care Med. 157(3 Part 1):928–37.

Sherrill DL, Krzyzanowski M, Bloom JW, Lebowitz MD (1991). Respiratory effects of non-tobacco cigarettes: a longitudinal study in general population. Int J Epidemiol. 20:132–7.

Sidney S, Quesenberry CP, Friedman GD, Tekawa IS (1997). Marijuana use and cancer incidence (California, United States). Cancer Causes Control. 8(5):722–8.

Sidney S (2002). Cardiovascular consequences of marijuana use. J Clin Pharmacol. 42(11 Suppl):64S–70S.

Smith MA, Gloekler-Reiss LA, Gurney J, Ross J (2000). Leukemia. In: Ries L, Smith MA, Gurney JG, et al., editors. SEER Cancer Statistics Review, 1973-1997. Bethesda: National Cancer Institute:17–34.

Takematsu M, Hoffman RS, Nelson LS, Schechter JM, Moran JH, Wiener SW (2014). A case of acute cerebral ischemia following inhalation of a synthetic cannabinoid. Clin Toxicol. 52(9):973.

Tan C, Hatam N, Treasure T (2006). Bullous disease of the lung and cannabis smoking: insufficient evidence for a causative link. J R Soc Med. 99(2):77–80.

Tan WC, Lo C, Jong A, Xing L, Fitzgerald MJ, Vollmer WM, et al. (2009). Marijuana and chronic obstructive lung disease: a population-based study. Can Med Assoc J. 180(8):814–20.

Tashkin DP (2015). Does marijuana pose risks for chronic airflow obstruction? Ann Am Thorac Soc. 12(2):235–36.

Tashkin DP, Calvarese BM, Simmons MS, Shapiro BJ (1980). Respiratory status of seventy-four habitual marijuana smokers. Chest. 78(5):699–706.

Tashkin DP, Coulson AH, Clark VA, Simmons M, Bourque LB, Duann S, et al. (1987). Respiratory symptoms and lung function in habitual heavy smokers of marijuana alone, smokers of marijuana and tobacco, smokers of tobacco alone, and non-smokers. Am Rev Respir Dis. 135:209–16.

Tashkin DP, Simmons MS, Sherrill DL, Coulson AH (1997). Heavy habitual marijuana smoking does not cause an accelerated decline in FEV1 with age. Am J Respir Crit Care Med. 155(1):141–8.

Tashkin DP, Simmons MS, Tseng CH (2012). Impact of changes in regular use of marijuana and/or tobacco on chronic bronchitis. COPD. 9(4):367–74.

Taylor DR, Poulton R, Moffitt TE, Ramankutty P, Sears MR (2000). The respiratory effects of cannabis dependence in young adults. Addiction. 95:1669–77.

Trabert B, Sigurdson AJ, Sweeney AM, Strom SS, Mcglynn KA (2011). Marijuana use and testicular germ cell tumors. Cancer. 117(4):848–53.

Ungerleider JT, Andrysiak T, Tashkin DP, Gale RP (1982). Contamination of marihuana cigarettes with pathogenic bacteria -- possible source of infection in cancer patients. Cancer Treat Rep. 66:589–91.

Van Hoozen BE, Cross CE (1997). Marijuana. Respiratory tract effects. Clin Rev Allergy Immunol. 15(3):243-69.

Wang X, Derakhshandeh R, Narayan S, Luu E, Le S, Danforth OM, et al. (2014). Brief exposure to marijuana secondhand smoke impairs vascular endothelial function [abstract]. Circulation. 130:A19538.

Wolff V, Armspach JP, Lauer V, Rouyer O, Bataillard M, Marescaux C, et al. (2013). Cannabis-related stroke: myth or reality? Stroke. 44(2):558–63.

Wolff V, Lauer V, Rouyer O, Sellal F, Meyer N, Raul J, et al. (2011). Cannabis use, ischemic stroke, and multifocal intracranial vasoconstriction: a prospective study in 48 consecutive young patients. Stroke. 42(6):1778–80.

Wolff V, Zinchenko I, Quenardelle V, Rouyer O, Geny B (2015). Characteristics and prognosis of ischemic stroke in young cannabis users compared with non-cannabis users. J Am Coll Cardiol. 66(18):2052–3. doi:10.1016/j.jacc.2015.08.867.

Wu TC, Tashkin DP, Djahed B, Rose JE (1988). Pulmonary hazards of smoking marijuana as compared with tobacco. NEJM. 318(6):347-51.

Zhang Z, Morgenstern H, Spitz MR, Tashkin DP, Yu GP, Marshall JR, et al. (1999). Marijuana use and increased risk of squamous cell carcinoma of the head and neck. Cancer Epidemiol Biomarkers Prev. 8(12):1071–8.

Zhang LR, Morgenstern H, Greenland S, Chang SC, Lazarus P, Teare MD, et al. (2015). Cannabis smoking and lung cancer risk: pooled analysis in the International Lung Cancer Consortium. Int J Cancer. 136(4):894-903.

Zhu K, Levine RS, Brann EA, Hall HI, Caplan LS, Gnepp DR (2002). Case-control study evaluating the homogeneity and heterogeneity of risk factors between sinonasal and nasopharyngeal cancers. Int J Cancer. 99(1):119–23.


Chapter 8

Berk M, Brook S, Trandafir AI (1999). A comparison of olanzapine with haloperidol in cannabis-induced psychotic disorder: a double-blind randomized controlled trial. Int Clin Psychopharmacol. 14(3):177-80.

Coffey C, Carlin JB, Lynskey M, Li N, Patton GC (2003). Adolescent precursors of cannabis dependence: findings from the Victorian Adolescent Health Cohort Study. Brit J Psychiat. 182:330–6.

Crippa JA, Derenusson GN, Chagas MH, Atakan Z, Martín-Santos R, Zuardi AW, et al. (2012). Pharmacological interventions in the treatment of the acute effects of cannabis: a systematic review of literature. Harm Reduct J. 9:7.

Danovitch I, Gorelick DA (2012). State of the art treatments for cannabis dependence. Psychiatr Clin North Am. 35(2):309–26.

EMCDDA (2013). Drug treatment overview for Netherlands [website]. Lisbon: European Monitoring Centre for Drugs and Drug Addiction (http://www.webcitation.org/6S4yjPY59, accessed 15 June 2015).

EMCDDA (2015) Prevention of addict behaviors. Updated and expanded edition on prevention of substance abuse. Lisbon: European Monitoring Centre for Drugs and Drug Addiction (http://www.emcdda.europa.eu/publications/insights/preventing-addictive-behaviours, accessed 05 September 2015.

Faggiano F, Vigna-Taglianti F, Burkhart G, Bohrn K, Cuomo L, Gregori D, et al. (2005). School-based prevention for illicit drugs’ use. Cochrane Database Syst Rev. (2):CD003020.

Faggiano F, Vigna-Taglianti F, Burkhart G, Bohrn K, Cuomo L, Gregori D, et al. (2010). The effectiveness of a school-based substance abuse prevention program: 18-Month follow-up of the EU-Dap cluster randomized controlled trial. Drug Alcohol Depend. 108(1–2):56–64.

Faggiano F, Minozzi S, Versino E, Buscemi D (2014). Universal school-based prevention for illicit drug use. Cochrane Database Syst Rev. (12):CD003020. doi: 10.1002/14651858.CD003020.pub3.

Ferri M, Allara E, Bo A, Gasparrini A, Faggiano F (2013). Media campaigns for the prevention of illicit drug use in young people. Cochrane Database Syst Rev. (6):CD009287. doi: 10.1002/14651858.CD009287.pub2.

Fisher BA, Ghuran A, Vadamalai V, Antonios TF. (2005). Cardiovascular complications induced by cannabis smoking: a case report and review of the literature. Emerg Med J. 22:679–80.

Florez-Salamanca L, Secades-Villa R, Budney AJ, Garcia-Rodriguez O, Wang S, Blanco C (2013) Probability and predictors of cannabis use disorders relapse: results of the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). Drug Alcohol Depend. 132(1-2):127-33 (http://dx.doi.org/10.1016/j.drugalcdep, accessed 05 September 2015).

Foxcroft DR, Tsertsvadze A (2011). Universal family-based prevention programs for alcohol misuse in young people. Cochrane Database Syst Rev. 2011 Sep (9):CD009308.

Foxcroft DF (2014) Can prevention classification be improved by considering the function of prevention? Prev Sci. 15:818–22.

Gates S, McCambridge J, Smith L, Foxcroft D (2006). Interventions for prevention of drug use by young people delivered in non-school settings. Cochrane Database Syst Rev. (1):CD005030.

Hall W, Degenhardt L (2015). High potency cannabis: a risk factor for dependence, poor psychosocial outcomes, and psychosis. BMJ. 350:h1205. doi:10.1136/bmj.h1205.

Hall WD, Pacula RL (2010). Cannabis use and dependence: public health and public policy (reissue of first edition 2003). Cambridge: Cambridge University Press.

Jepson RG, Harris FM, Platt S, Tannahill C (2010) The effectiveness of interventions to change six health behaviours: a review of reviews. BMC Public Health. 10:538.

Jones L, Sumnall H, Witty K, Wareing M, McVeigh J, Bellis M (2006). A review of community-based interventions to reduce substance misuse among vulnerable and disadvantaged young people. Liverpool: National Collaborating Centre for Drug Prevention.

Kosior DA, Filipiak KJ, Stolarz P, Opolski G (2001). Paroxysmal atrial fibrillation following marijuana intoxication: a two-case report of possible association. Int J Cardiol. 78:1834.

Marshall K, Gowing L, Ali R, Le Foll B (2014). Pharmacotherapies for cannabis dependence. Cochrane Database Syst Rev. (12):CD008940. doi:10.1002/14651858.CD008940.pub2.

McGrath Y, Sumnall H, McVeigh J, Bellis M (2006). Drug use prevention among young people: a review of reviews. London: National Institute for Health and Clinical Excellence (NICE).

Medina-Mora ME (2005). Prevention of substance abuse: a brief overview. World Psychiatry. 4(1):25–30.

Perkonigg A, Goodwin RD, Fiedler A, Behrendt S, Beesdo K, Lieb R, et al. (2008). The natural course of cannabis use, abuse, and dependence during the first decades of life. Addiction. 103:43949.

Roffman R, Stephens R, editors (2006). Cannabis dependence: its nature, consequences and treatment. Cambridge: Cambridge University Press.

Rubio F, Quintero S, Hernandez A, Fernandez S, Cozar L, Lobato IM, et al. (1993). Flumazenil for coma reversal in children after cannabis. Lancet. 341:10289.

Springer JF, Sale E, Hermann J, Sambrano S, Kasim R, Nistler M (2004). Characteristics of effective substance abuse prevention programs for high-risk youth. J Prim Prev. 25:171219.

Tobler NS, Roona MR, Ochshorn P, Marshall DG, Streke AV, Stackpole KM (2000). School-based adolescent drug prevention programs: 1998 meta-analysis. J Prim Prev. 20:275336.

Sanders MR (1999). Triple P-Positive Parenting Program: towards an empirically validated multilevel parenting and family support strategy for the prevention of behavior and emotional problems in children. Clin Child Fam Psychol Rev. 2(2):71–90.

WHO (2015), Psychosocial interventions for the management of cannabis dependence (Updated 2015), available at:

http://www.who.int/mental_health/mhgap/evidence/resource/substance_use_q4.pdf?ua=1